Close

Needham & Company Reiterates a 'Buy' on Seattle Genetics (SGEN); Adcetris Data in Combination with AVD Supportive of Potential Role in Front Line Therapy Dec 14, 2011 07:40AM
Notable Analyst Rating Changes 11/11: (LSCC) (GNW) (DNDN) Upgraded; (CAG) (BRLI) (FSLR) Downgraded Nov 11, 2011 11:26AM
Needham & Company Assumes Coverage on Seattle Genetics (SGEN) at Buy; 3Q11 Review and ASH Meeting Preview Nov 11, 2011 09:12AM
Notable Analyst Rating Changes 09/16: (EBAY) (LYG) (REV) Upgraded; (RIMM) (ADBE) (SSYS) Downgraded Sep 16, 2011 11:01AM
Needham & Company Reiterates a 'Buy' on Seattle Genetics; As the School Year Begins, So Does Commercial Life for SGEN Aug 22, 2011 03:06PM


Jul 12, 2011 03:33PM Needham & Company maintains a 'Buy' on Seattle Genetics (SGEN); FDA Briefing Documents for the BLAs of ADCETRIS
Jun 8, 2011 08:07AM Needham & Company Maintains a 'Buy' on Seattle Genetics (SGEN); ASCO Meeting Highlights Include Durable Responses Induced By B. Vedotin
May 19, 2011 08:24AM Needham & Co Highlights Seattle Genetics (SGEN), Pharmacyclics (PCYC), and Dendreon (DNDN) Ahead of ASCO
May 6, 2011 09:45AM Needham & Company Reiterates a 'Buy' on Seattle Genetics (SGEN); Raising PT
Apr 12, 2011 07:39AM Needham & Company on Biotechnology & Life Sciences: Oncology / Hematology Review from the 2011 Needham Healthcare Conference
Feb 9, 2011 08:45AM Needham & Company Reiterates a 'Buy' on Seattle Genetics (SGEN); Trials/Other Pipeline Data Set the 2011 Mission
Feb 1, 2011 04:40PM Seattle Genetics (SGEN) To Offer Common Shares
Jan 5, 2011 08:26AM Needham & Company Reiterates a 'Buy' on Seattle Genetics (SGEN); 2011 May Be a Transformational Year
Dec 6, 2010 07:59AM Needham & Company reiterates a 'Buy' on Seattle Genetics (SGEN); B is for BLA, and Ved is for Very Exemplary Data - Pivotal Trial Results
Nov 2, 2010 08:17AM Needham & Company Reiterates a 'Buy' on Seattle Genetics (SGEN)
Sep 27, 2010 11:13AM Needham & Company Lifts Target On Seattle Genetics (SGEN) Following Positive Data
Sep 13, 2010 08:50AM Needham & Company Defending Seattle Genetics (SGEN); Remain Positively Inclined Towards B. vedotin and Current ADC Platform
Jul 28, 2010 08:07AM Needham & Company Reiterates a 'Buy' on Seattle Genetics (SGEN); Anticipation of Sentinel Clinical Trial Events Expected in 2H10
May 21, 2010 10:25AM 2010 ASCO Meeting Preview - Needham & Co Highlights ArQule (ARQL), Celldex (CLDX), Pharmacyclics (PCYC), and Seattle Genetics (SGEN)
Oct 5, 2009 10:16AM Morning Movers 10/05: DEPO, AVII, OPTV, CRXX, UCTT, CPRX Higher; FOLD, FTBK, SGEN, SCLN, REED Lower
Jul 23, 2009 10:01AM Needham Comments on "Who's Next" In Biotech After Bristol-Myers (BMY) Buys Medarex (MEDX)